Patients’ preference of established and emerging treatment options for obstructive sleep apnoea

Obstructive sleep apnoea (OSA) is the most common form of sleep-disordered breathing, affecting up to 10% of middle-aged men and 3% of middle-aged women (1). It is characterised by intermittent and repeated episodes of upper airway obstruction during sleep and can result in irregular breathing at night and excessive sleepiness during the day (2). OSA is also associated with several co-morbidities, including hypertension (3), ischaemic heart disease (4), stroke (5), congestive heart failure (6), obesity (7), and diabetes (8)